IGF1 and Alzheimer disease: In AD, brain insulin and IGF resistance result in decreased signaling through phosphoinositol-3-kinase (PI3K), Akt [50, 51], and Wnt/β-catenin [52], and increased activation of glycogen synthase kinase 3β (GSK-3β) [53-57].